Novamind expands its treatment footprint via a new partnership with Uruguay-based Bienstar Wellness.
MindMed Inc
Company Brief
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The company's immediate priority is to address the opioid crisis by developing a non- hallucinogenic version of the psychedelic ibogaine. In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for Adult ADHD, is pursuing experiential psychedelic assisted therapy for the treatment of anxiety, and is collaborating on a clinical trial to evaluate LSD for the treatment of cluster headaches. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDFand in Germany under the symbol DE:BGHM.
Highlights
Related Articles
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways provides further details on its Phase IIb results for the treatment of Treatment Resistant Depression, including reporting of additional "patient improvements".
TSI EDITOR |
2021-12-01
Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing
UK-based Albert Labs receives conditional approval from the Canadian Securities Exchange (CSE) to commence trading under the symbol "ABRT". Trading expected to commence in early 2022.
TSI EDITOR |
2021-11-30
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
Cybin seeks FDA approval for a new Phase 2 clinical trial aimed at treating "distress" among frontline healthcare practitioners.
TSI EDITOR |
2021-11-30
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
atai Life Sciences adds to its holding in Compass Pathways, raising its ownership interest back to 20.8%.
TSI EDITOR |
2021-11-29
Red Light Holland Reports Second Quarter 2021 Results
Red Light Holland reports its results for Q2 fiscal 2021. - Quarterly revenues up to CAD$485,738 - A 64% increase in gross profit - 56% increase in the number of retail outlets selling TRIP products
TSI EDITOR |
2021-11-29
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now